Brief: AIM ImmunoTech Announces Interim Report Data From Study of Ampligen Combined with Pembrolizumab For Treatment Of Recurrent Ovarian Cancer
10/04/2024 13:28
April 10 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES POSITIVE TOP-LINE,
PROTOCOL-PLANNED
INTERIM REPORT DATA FROM THE STUDY OF AMPLIGEN COMBINED WITH
PEMBROLIZUMAB FOR THE TREATMENT OF RECURRENT OVARIAN CANCER
Source text for Eikon: ID:nGNX6C4w0P
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential